1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Standard Chem & Pharm Co. Ltd.

Standard Chem & Pharm Co. Ltd.

1720.TW
Standard Chem & Pharm Co. Ltd.TW flagTaiwan Stock Exchange
63.90
TWD
+0.30
- -
11.42BMarket Cap
Standard Chem & Pharm Co. Ltd.
1720.TW
(Taiwan Stock Exchange)

Recent

price

63.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
17.32
19.78
20.03
17.74
18.44
18.59
20.56
21.54
20
22.03
24.09
25.76
32.74
34.92
37.99
- -
39.32
Revenue per Share
1.26
1.47
1.64
1.73
2.09
1.95
1.9
2.03
2.09
2.11
2.93
3.95
4.56
4.67
4.93
- -
5.19
Basic EPS, GAAP
-0.94
0.72
1.37
0.04
2.26
2.6
0.71
1.81
1.77
2.65
3.19
3.41
0.17
3.96
6.13
- -
7.07
Free Cash Flow per Basic Share
1.49
0.47
1
1.18
2.5
1
1.5
1.5
1.6
1.5
1.5
1.8
2.5
2.5
2.7
- -
- -
Dividend per Share
12.06
12.27
12.62
15.95
12.45
13.87
14.73
15.5
15.72
16.04
17.21
19.8
20.96
22.76
25.36
- -
27.28
Book Value per Share
16.48
16.68
17.75
19.95
19.36
21
22.81
22.85
23.14
25.46
26.96
36.8
40.35
44.34
49.07
- -
50.82
Tangible Book Value per Share
167
168
168
172
179
179
179
179
179
179
179
179
179
179
179
- -
179
Basic Weighted Avg Shares
2,894
3,332
3,374
3,054
3,296
3,321
3,674
3,849
3,573
3,937
4,305
4,604
5,851
6,240
6,789
7,023
7,023
Sales/Revenue/Turnover
11.17
6.23
6.53
8.68
11.45
11.55
11.38
14.07
11.16
12.95
16.26
19.06
19.42
20.04
20.74
19.37
19.37
Operating Margin (%)
119
147
137
141
153
165
192
193
198
229
234
221
299
348
405
434
434
Depreciation Expense
210
247
276
298
374
348
340
363
374
376
524
707
815
835
881
928
928
Net Income, GAAP
22.56
21
14.44
17.23
16.32
20.66
19.48
21.24
17.3
19.7
19.07
17.45
17.59
19.47
20.47
17.07
17.07
Effective Tax Rate (%)
7.26
7.41
8.18
9.77
11.36
10.47
9.26
9.44
10.48
9.56
12.17
15.35
13.94
13.38
12.97
13.21
13.21
Profit Margin (%)
1,426
1,313
1,403
1,495
1,398
1,426
1,311
1,517
1,611
1,801
1,951
3,068
2,710
3,047
3,341
3,304
3,304
Working Capital
223
30
40
127
181
213
47
187
152
144
202
290
419
445
368
204
204
LT Debt
2,914
2,960
3,155
3,582
3,606
3,887
4,197
4,202
4,246
4,646
4,906
6,800
7,436
8,137
8,976
9,287
9,287
Total Equity
6.97
4.29
4.76
5.21
7.34
6.76
6.89
8.11
6
7.11
9.45
9.69
9.94
10.08
11.1
10.93
10.93
Return on Invested Capital (%)
5.16
8.06
8.9
8.49
10.76
9.83
8.29
7.1
7.26
6.05
8.53
8.97
5.92
6.16
5.59
6.86
6.86
Return on Capital (%)
10.29
12.09
13.17
12.25
15.06
14.8
13.31
13.45
13.42
13.27
17.64
21.38
22.39
21.37
20.48
19.72
19.72
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
529
1,053
925
LT Borrowings
34
20
5
LT Finance Leases
210
205
199
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
179
179
179
Market Capitalization
10,169
10,128
10,521

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
5,224
5,336
5,461
Cash, Cash Equivalents & STI
1,983
2,182
2,385
Accounts Receivable, Net
1,163
1,149
1,085
Inventories
1,600
1,590
1,569
Total Current Liabilities
2,527
2,217
2,157
Payables & Accruals
- -
- -
- -
ST Debt
529
1,053
925
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.53%
14.23%
3.46%
Free Cash Flow
236.96%
444.12%
15.35%
Net Income, GAAP
11.08%
12.68%
5.36%
Sales/Revenue/Turnover
8.07%
10.58%
3.44%
Total Cash Common Dividend
- -
- -
3.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1,493
1,509
1,646
1,592
6,240
2024
1,614
1,760
1,742
1,673
6,789
2025
1,640
1,828
1,770
1,785
7,023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1.18
1.33
1.25
- -
4.67
2024
1.41
1.21
1.22
- -
4.93
2025
1.09
1.1
1.72
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.5
2024
- -
- -
- -
- -
2.7
2025
- -
- -
- -
- -
- -
Similar Companies
Guardion Health Sciences, Inc. (GHSI)
Western Sierra Resource Corporation (WSRC)
Divi's Laboratories Limited (DIVISLAB.NS)
Jacobson Pharma Corporation Limited (2633.HK)
MGC Pharmaceuticals Limited (MXC.AX)
Global Hemp Group Inc. (GBHPF)
Business
Standard Chem. & Pharm. Co., Ltd. is a pharmaceutical company based in Tainan City, Taiwan, founded in 1967. The company specializes in the research, development, manufacture, and sale of pharmaceutical products, dietary supplements, and active pharmaceutical ingredients (APIs). Its product portfolio includes finished dosage forms for therapeutic areas such as metabolic, respiratory, musculoskeletal, digestive, circulatory, cardiovascular, nervous systems, anti-infectives, urogenital system, sex hormones, and topical dermatology. The company also produces western medicines, nutritional and functional foods, biochemical nutrition products, and preventive medicines. In addition, Standard Chem. & Pharm. offers medical equipment, animal medicines, cosmetics, and milk powder. It operates as a Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO), focusing on innovative drug delivery systems including osmotic-controlled release, micro-encapsulation, pulsatile controlled-release, and lyophilization. Its manufacturing facilities hold approvals from health authorities in the United States, Japan, and Southeast Asian countries. Recent strategic developments include collaboration with major Japanese pharmaceutical companies to expand market presence, and forming strategic alliances with API manufacturers. The company continues to emphasize regulatory compliance and quality assurance aligned with international standards while pursuing innovative technology and superior customer service. These initiatives align with the company’s long-standing corporate philosophy centered on professionalism, excellence, social responsibility, and sustainable growth in the global pharmaceutical industry. Standard Chem. & Pharm. primarily serves domestic and international markets, maintaining a strong reputation for high-quality pharmaceutical solutions.